Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ANGLE To Acquire Remaining Stake In US Subsidiary For GBP467,500 (ALLISS)

Mon, 05th Nov 2018 12:11

LONDON (Alliance News) - Liquid biopsy company ANGLE PLC said on Monday it has agreed to acquire the remaining shares in US subsidiary ANGLE North America Inc it does not own from Parsotix inventor Georgi Hvichia.

ANGLE will acquire 303,335 shares, reflecting a 9.5% stake in ANGLE North America, through the issue of 1.0 million shares at a price of 46.75 pence per share, or GBP467,500.

Shares in ANGLE were up 0.4% at 46.95 pence on Monday.

Following this transaction, ANGLE will fully own ANGLE North America, while Hvichia will hold 1.1 million shares in ANGLE, reflecting a 0.8% interest. In addition, ANGLE will now fully own all of its group companies.

"We are pleased to reach agreement with Georgi Hvichia, the original inventor of the Parsortix microfluidic technology, to acquire his remaining shareholding in our US operating subsidiary in exchange for ANGLE shares. Hvichia will remain involved through his new role as a scientific advisory board member," said Chief Executive Andrew Newland.

ANGLE will have 143.5 million shares issued overall following this transaction.

More News
20 Oct 2020 14:18

IN BRIEF: Angle Says FDA Accepts Parsotix Submission For Breast Cancer

IN BRIEF: Angle Says FDA Accepts Parsotix Submission For Breast Cancer

Read more
20 Oct 2020 08:58

FDA accepts Angle's review submission for Parsortix PC1

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the US Food and Drug Administration (FDA) has completed its administrative review, and accepted the company's submission for substantive review.

Read more
28 Sep 2020 19:33

IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix

IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix

Read more
20 Aug 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
14 Aug 2020 12:41

Angle's Parsortix Able To Predict Patients' Response To Treatment

Angle's Parsortix Able To Predict Patients' Response To Treatment

Read more
20 Jul 2020 20:03

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

Read more
20 Jul 2020 10:16

Angle's 'Parsortix' advantageous in breast cancer in new research

(Sharecast News) - Angle announced on Monday that the University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC), highlighting advantages of a 'Parsortix' liquid biopsy, compared to standard-of-care tissue biopsy.

Read more
25 Jun 2020 12:22

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

Read more
18 Jun 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
10 Jun 2020 16:41

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

Read more
12 May 2020 18:54

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

Read more
12 May 2020 08:58

Angle upbeat on recent research using 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago in Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer, on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).

Read more
28 Apr 2020 12:28

UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE

UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE

Read more
28 Apr 2020 10:03

Angle works with skeleton R&D crew during lockdown

(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.

Read more
31 Mar 2020 12:21

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.